News
Carbon

CARBON Newsletter (27 July) - Your Latest News About CRISPR in AgroBio

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jul. 27, 2022
News

CRISPR AgroBio News (CARBON) is a new initiative from CRISPR Medicine News. CARBON will bring you the latest news on how CRISPR can shape agriculture for the future to guarantee food security in times of population growth and climate change.

To get more CRISPR AgroBio News delivered to your inbox, sign up to the free weekly CARBON Newsletter here.

Top picks

  • Researchers in Spain have developed two simple and effective CRISPR-based methods for detecting infection with three common RNA viruses in Nicotiana benthamiana plants. In one setting, Cas13a was used in crude leaf extracts without prior amplification together with crRNA targeting either Tobacco mosaic virus, Tobacco etch virus or Potato virus X. Upon detection of the viral RNA, collateral cleavage of an ssRNA probe labelled with a fluorophore and a quencher led to fluorescence readout. In another setting, Cas12a was used similarly after PCR or isothermal amplification, and this method could also be used for multiplexed detection in plants with mixed infections.
  • Agroinfection with a potato virus X (PVX)-derived vector has been used to deliver part of the CRISPR toolkit to Nicotiana benthamiana. The Spanish researchers behind the achievement used the vector to deliver gRNAs to plants already transformed with the remaining complementary CRISPRa components that mediate strong programmable transcriptional activation in plants. After spraying N. benthamiana leaves with the virus vector, the gRNAs mediated a strong activation response in different target genes that moved locally and systemically.

Technical advances

Disease control

Detection

Climate change

Industry

Reviews

Tags

HashtagArticleHashtagNewsHashtagCARBONHashtagCARBON Newsletter

News: CARBON Newsletter (27 July) - Your Latest News About CRISPR in AgroBio
CLINICAL TRIALS
Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Duchenne Muscular Dystrophy, DMD, (NCT06594094)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine